Enrich your health with MF Plus

ALFACHOLINE® THERAPY

Cell Membrane | Liver | Cardiovascular | Anti-Aging | Enhance Cognitive Abilities

A ground-breaking patented solution formulated to bring out the best in you via the powerful benefits of Phosphocholine Complex. Its synergistic effects work to boost heart, liver, and cardiovascular health, enhance your cognitive abilities, and strengthen your cellular membrane!

Your body's levels of phosphatidylcholine and choline can be influenced by various factors, including your diet, health conditions, medications, and even your genetic makeup. Keeping these levels up is key to maintaining good health and avoiding potential health risks.

HEALTH BOOSTER:
PHOSPHOCHOLINE COMPLEX

A unique blend carefully formulated to support essential cellular functions. This comprehensive complex contains a selection of vital components that play integral roles in various physiological processes:

Enhancing Cell Membranes:

The Phosphocholine Complex is tailored to enhance the integrity and flexibility of cell membranes, which serve as the protective barriers surrounding cells. By promoting membrane health, this complex aids in facilitating effective communication between cells and maintaining their overall functionality.

Nurturing Cognitive Health:

A key focus of the Phosphocholine Complex is to nurture brain health. Through its formulation, this complex helps in the production of a vital neurotransmitter associated with memory, learning, and cognitive performance. This support for neurotransmitter synthesis can contribute to improved cognitive abilities and mental clarity.

Building Blocks for Vital Molecules:

The intricate blend of the Phosphocholine Complex provides essential building blocks that are utilized in the synthesis of crucial molecules within our body. These molecules play pivotal roles in energy metabolism and other essential cellular processes that are fundamental to overall well-being.

By harnessing the synergistic benefits of its constituent components, the Phosphocholine Complex is designed to provide holistic support for your cellular vitality, cognitive health, and overall bodily functions.

FACTORS: AFFECTING PHOSPHATIDYLCHOLINE AND CHOLINE LEVELS

Diet	Health Conditions	Medication	Genetic Factors
Insufficient intake of choline-rich foods may lead to low choline levels.	Conditions like fatty liver disease and kidney dysfunction can disrupt choline metabolism.	Certain drugs, like anticonvulsants or medicine for high cholesterol, can hinder how your body absorbs and uses choline.	Your genetic variations can also affect how your body makes and uses choline and phosphatidylcholine.

SOLUTION: PHOSPHOCHOLINE COMPLEX

While your body naturally produces some Phosphatidylcholine through CDP Choline pathways, it often requires more than it generates. Alfacholine Therapy provides the essential components – Phosphocholine complex – to enhance natural choline production. This ensures your cells, heart, liver, and brain access the resources needed for optimal function and your overall well-being.

OPTIMAL DELIVERY WITH LIPOSOMAL TECHNOLOGY

This liposomal delivery system enhances ALFACHOLINE® Therapy's bioavailability by ensuring that its constituents reach their intended target-specific organs. The liposomes reach their intended target, which is the liver. Here, they break down, releasing all the bioactive substances into the circulatory and initiating their mechanism of action.

Liver is the primary site of action for Alfacholine, their functions involve the production of VLDL and the initiation of FXR activation for lipid metabolism.Simultaneously, free Choline returns to the circulatory system, enhancing the choline pool through the hepatic vein. It then exerts its mechanism of action by reducing homocysteine and cholesterol while promoting acetylcholine production and rejuvenation of the celullar membrane.



Fig. 1: AlfaCholine: Liposomal Solution

GENERAL PROTOCOL

Infusion Preparation:

Mix 10ml solution with 250ml of 5% Dextrose or Glucose.

Length of infusion:

Please allow 60 - 100 minutes of infusion time.

Storage:

4°C - 16°C. Away from direct sunlight. Stable under room temperature < 25°C.

Protocol:

Corrective: One-course treatment is a minimum of 10 sessions, 1 vial per session. Administration frequency is once or twice a week in a 2-to-3-month timeframe.

Maintenance:
Daily oral supplementation of Alfacholine® softgel, 1 softgel per day.

Shelf Life: 2 years.

OPTIMIZING WELLNESS: ALFACHOLINE® THERAPY'S IMPACT ON LIVER, CARDIOVASCULAR, AND COGNITIVE HEALTH.

LIVER HEALTH

Reduction Of Visceral Fat

Optimize the elimination of triglycerides and cholesterol from the liver. Facilitating lipid breakdown and efficient transport, they act as a barrier against visceral fat accumulation in the liver.

FXR (farnesoid X receptor) Activation

FXR activation promotes the reduction of visceral fat, utilisation of lipids for energy production and promote liver homeostasis, reducing the risk for developing fatty liver.

Anti-Inflammatory Effects

Possessing both anti-inflammatory and antioxidant attributes that mitigate liver inflammation and counteract oxidative stress, ensuring the comprehensive health of the liver.

Repair and Regenerate Liver Cells

Promote the rejuvenation and revitalization of liver health by fortifying and enhancing the fluidity of the cellular membrane within the liver.

CARDIOVASCULAR HEALTH

Maintains Healthy Cholesterol Levels

Reduce the LDL cholesterol uptake in gastrointestinal layer, which helps to maintains a harmonious equilibrium between HDL and LDL cholesterol, effectively reducing the risk of hypercholesterolemia.

Regulates Homocysteine Levels

Improve the choline reservoir, enabling the generation of betaine. Greater choline availability ensures ample betaine supply, supporting the reduction of homocysteine.

Improves Lipid Transport and Metabolism

Enhance lipid transport and metabolism which promote efficient clearance of cholesterol from the bloodstream, reducing the risk of plaque formation and cardiovascular disease.

COGNITIVE HEALTH

Brain-boosting ingredients:

1. *Cognitive-Enhancing Formula*

   Nootropic with blood-brain barrier properties, offering efficient formation of acetylcholine and uridine, a precursor for both neurotransmitter synthesis and synaptic connection, which plays a key role in memory, learning, and cognitive processes.

2. *Preserving of Optimal Brain Integrity*

   Promote healthy membrane fluidity, neuroprotection, and neuroplasticity, which are essential for supporting the survival and maintenance of brain cells. This is achieved by providing structural support to cellular membranes, shielding them from oxidative stress, and maintaining their integrity. Neuroplasticity is critical for learning, memory formation, and adapting to new experiences.

FAQ – FREQUENTLY ASKED QUESTIONS

Are there any risks or side effects associated with Alfacholine® Therapy?

Like any medical procedure, there are potential risks and side effects associated with intravenous therapy. These may include allergic reactions, injection site reactions, or rare complications. It is important to discuss these risks with a healthcare professional.

What is the onset of action with Alfacholine® Therapy?

The onset of action with Alfacholine® Therapy is typically rapid. Since Alfacholine® Therapy is directly introduced into the bloodstream, it can quickly reach its target tissues and exert its effects.

Is Alfacholine® Therapy safe for everyone?

Alfacholine® Therapy should be performed under medical supervision. It is generally safe when administered by qualified healthcare professionals, but individual circumstances and medical history may affect its suitability. It is important to consult with a healthcare professional to determine if this therapy is appropriate for you.

Concerning diabetic patients, can normal saline be used as a replacement for Dextrose or Glucose solution to prepare Alfacholine® Therapy infusion?

No, Alfacholine® Therapy liposomal structure is unstable when reconstituted with normal saline; hence only use Glucose or Dextrose 5 % solution, even in diabetic patients.

Does FDA approve Alfacholine® solution?

Alfacholine® Therapy is legally compounded for physician use, compliance with AMG law, Germany.

What is the upper tolerable dose for Alfacholine® Therapy?

When administered intravenously, the upper limit of Alfacholine® Therapy can vary depending on factors such as individual health conditions, tolerance, and specific treatment goals. Generally, the maximum dosage for Alfacholine® Therapy is two vials per week with at least 1-day intervals between injections. Two Alfacholine® Therapy sessions are equivalent to 1712mg Phosphocholine Complex.

What are the side effects?

Severely atherosclerotic patients, individuals undergoing daily treatments, or those without a gall bladder may experience temporary diarrhoea. Patients may also experience temporary increase in LDL cholesterol and Liver enzymes at the start of treatment, which will return to normal with ongoing therapy and post maintenance therapy. Fatigue and thrombophlebitis at the infusion site are also possible side effects.

How to avoid thrombophlebitis?

Increase the Dextrose or Glucose solution from 250ml to 500ml and the infusion time by 90 minutes – 120 minutes.

What is the best storage condition?

Alfacholine® Therapy is stable under room temperature <25°C. Although Alfacholine® Therapy is stable at room temperature, storing the vial in a refrigerator until ready to use is advisable. All opened vials must be used immediately so as to avoid contamination. Take out the Alfacholine® Therapy from the refrigerator 1 hour prior to mixing it with Dextrose or Glucose solution.

COMPARISON : ALFACHOLINE® SOFTGEL (SUPPLEMENT) WITH ALFACHOLINE® THERAPY (INTRAVENOUS)

Product specification	AlfaCholine® Softgel Supplement	AlfaCholine® Therapy Intravenous Therapy
ADMINISTRATION	Oral supplementation	Intravenous injection
ABSORPTION	Absorbed in the gastrointestinal tract	Direct into the bloodstream; the liver is the primary site of action
BIOAVAILABILITY	Variable, influenced by individual factors and digestion bioavailability ≈ 60%.	Intravenous administration provides immediate and complete absorption, resulting in high bioavailability close to 100%.
ONSET OF ACTION	Gradual	Rapid
INDICATION OF USE	General supplementation for brain health, liver support, and cognitive function. Suitable for prevention and maintenance course.	Medical procedures requiring immediate Choline and Phosphatidylcholine administration, fatty liver and cardiovascular conditions (homocysteine/lipid plaques). Suitable for the corrective course.
SAFETY	Generally safe when used as directed.	Requires medical supervision, potential risks and side effects associated with intravenous administration.
CONTRAINDICATION	Allergies or sensitivities to phosphatidylcholine, choline or other ingredients.	Known hypersensitivity to phosphatidylcholine/choline, certain medical conditions requiring caution with intravenous administration.

Specific indications, safety, and contraindications may vary depending on individual health conditions. It is essential to consult with healthcare professionals for personalised advice and recommendations.

REFERENCES:

1. Maria De Jesus Moreno Moreno (2003). Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate: A multicenter, double-blind, randomized, placebo-controlled trial. , 25(1), 0–193. doi:10.1016/s0149-2918(03)90023-3
2. Magaquian, D., Delgado Ocaña, S., Perez, C. et al. Phosphatidylcholine restores neuronal plasticity of neural stem cells under inflammatory stress. Sci Rep 11, 22891 (2021). https://doi.org/10.1038/s41598-021-02361-5
3. Donkers, Joanne M.; Roscam Abbing, Reinout L.P.; van de Graaf, Stan F.J. (2018). Developments in bile salt based therapies: a critical overview. Biochemical Pharmacology, (), S0006295218305252–. doi:10.1016/j.bcp.2018.12.018
4. Jiao Y, Lu Y, Li XY. Farnesoid X receptor: a master regulator of hepatic triglyceride and glucose homeostasis. Acta Pharmacol Sin. 2015 Jan;36(1):44-50. doi: 10.1038/aps.2014.116. Epub 2014 Dec 15. PMID: 25500875; PMCID: PMC4571315.
5. Cantafora A, Masella R, Angelico M, Gandin C, Blount RJ, Peterson SW. Effect of intravenous polyunsaturated phosphatidylcholine infusion on insulin receptor processing and lipid
6. composition of erythrocytes in patients with liver cirrhosis. Eur J Clin Invest. 1992;22(12):777- 782.
7. Howard AN, Patelski J. Effect of intravenous polyunsaturated phosphatidyl choline in experimental atherosclerosis. Verh Dtsch Ges Inn Med. 1972;78:1245-1248.
8. Zhang L, Wang YD, Chen WD, Wang X, Lou G, Liu N, Lin M, Forman BM, Huang W. Promotion of liver regeneration/repair by farnesoid X receptor in both liver and intestine in mice. Hepatology. 2012 Dec;56(6):2336-43. doi: 10.1002/hep.25905. PMID: 22711662; PMCID: PMC3477501.
9. Fang S. Bile Acid Receptor Farnesoid X Receptor: A Novel Therapeutic Target for Metabolic Diseases. J Lipid Atheroscler. 2017 Jun;6(1):1-7. https://doi.org/10.12997/jla.2017.6.1.1
10. Magaquian, D., Delgado Ocaña, S., Perez, C. et al. Phosphatidylcholine restores neuronal plasticity of neural stem cells under inflammatory stress. Sci Rep 11, 22891 (2021). https://doi.org/10.1038/s41598-021-02361-5
11. Joseph R. Herdy, Larissa Traxler, Ravi K. Agarwal, Lukas Karbacher, Johannes C.M. Schlachetzki, Lena Boehnke, Dina Zangwill, Doug Galasko, Christopher K. Glass, Jerome Mertens, Fred H. Gage, Increased post-mitotic senescence in aged human neurons is a pathological feature of Alzheimer's disease,Cell Stem Cell, Volume 29, Issue 12,2022,Pages 1637-1652.e6, https://doi.org/10.1016/j.stem.2022.11.010.
12. Tamura Y, Takata K, Matsubara K, Kataoka Y. Alpha-Glycerylphosphorylcholine Increases Motivation in Healthy Volunteers: A Single-Blind, Randomized, Placebo-Controlled Human Study. Nutrients. 2021 Jun 18;13(6):2091. doi: 10.3390/nu13062091. PMID: 34207484; PMCID: PMC8235064.
13. Schverer, Marina; O'Mahony, Siobhain M.; O'Riordan, Kenneth J.; Donoso, Francisco; Roy, Bernard L.; Stanton, Catherine; Dinan, Timothy G.; Schellekens, Harriët; Cryan, John F. (2020). Dietary Phospholipids: Role in Cognitive Processes Across the Lifespan. Neuroscience & Biobehavioral Reviews, (), S0149763419310346–. doi:10.1016/j.neubiorev.2020.01.012
14. Akbarzadeh A, Rezaei-Sadabady R, Davaran S, Joo SW, Zarghami N, Hanifehpour Y, Samiei M, Kouhi M, Nejati-Koshki K. Liposome: classification, preparation, and applications. Nanoscale Res Lett. 2013 Feb 22;8(1):102. doi: 10.1186/1556-276X-8-102. PMID: 23432972; PMCID: PMC3599573.
15. Shade CW. Liposomes as Advanced Delivery Systems for Nutraceuticals. Integr Med (Encinitas). 2016 Mar;15(1):33-6. PMID: 27053934; PMCID: PMC4818067.
16. Magee GA, French J, Gibbon B, Luscombe C. Bile salt/lecithin mixed micelles optimized for the solubilization of a poorly soluble steroid molecule using statistical experimental design. Drug Dev Ind Pharm. 2003 Apr;29(4):441-50. doi: 10.1081/ddc-120018379. PMID: 12737537.
17. Maciej Świątkiewicz , Paweł Grieb. Citicoline for Supporting Memory in Aging Humans. Aging and disease. 2022 https://doi.org/10.14336/AD.2022.0913
18. Wurtman RJ, Cansev M, Sakamoto T, Ulus I. Nutritional modifiers of aging brain function: use of uridine and other phosphatide precursors to increase formation of brain synapses. Nutr Rev. 2010 Dec;68 Suppl 2(Suppl 2):S88-101. doi: 10.1111/j.1753-4887.2010.00344.x. PMID: 21091953; PMCID: PMC3062998.
19. Gage M, Phillips K, Noh B, Yoon T. Choline-Based Multi-Ingredient Supplementation Can Improve Explosive Strength during a Fatiguing Task. International Journal of Environmental Research and Public Health. 2021; 18(21):11400. https://doi.org/10.3390/ijerph182111400
22. Herman TF, Santos C. First Pass Effect. [Updated 2022 Sep 24]. In: StatPearls [Internet].
23. Lieber CS. Prevention and treatment of liver fibrosis based on pathogenesis. Alcohol Clin Express. 1999;23(5):944-949.
24. Navder KP, Baraona E, Lieber CS. Polyenylphosphatidylcholine attenuates alcohol-induced fatty liver and hyperlipemia in rats. J Nutr. 1997;127(9):1800-1806
25. Buxton I.O., & Benet L.Z. (2015). Pharmacokinetics: the dynamics of drug absorption, distribution, metabolism, and elimination. Brunton L.L., & Chabner B.A., & Knollmann B.C.(Eds.), Goodman & Gilman's: The Pharmacological Basis of Therapeutics, 12e. McGraw Hill.
26. Borodin EA, Lanio ME, Khalilov EM, Markin SS, Torkhovskaia TI. [Extraction of cholesterol from biological membranes with positively charged micelles of phosphatidylcholine]. Biull Eksp Biol Med. 1985;99(2):164-166
27. Xu J, Fan Y, Yu Y, Han Y, Kang Q, Tan N, Yang Y, Chen H, Pan J, Xu X. A Multicenter Real-World Study Evaluating the Hepatoprotective Effect of Polyene Phosphatidylcholine Against Chronic Hepatitis B. Front Med (Lausanne). 2022 Jun 22;9:842098. doi: 10.3389/fmed.2022.842098. PMID: 35814776; PMCID: PMC9256938.
28. Ballinger AB, Forget D, Le Brun A, Farthing MJ. An evaluation of the safety of mixed micelles in healthy subjects. JPEN J Parenter Enteral Nutr. 1996 Mar-Apr;20(2):110-2. doi: 10.1177/0148607196020002110. PMID: 8676527.
29. Chiang Chia-Ming, Norman Weiner, Gastrointestinal uptake of liposomes. I. In vitro and in situ studies, International Journal of Pharmaceutics, Volume 37, Issues 1–2, 1987, Pages 75-85, ISSN 0378-5173.30. Duan RL, Sun X, Liu J, Gong T, Zhang ZR. Mixed micelles loaded with silybin-polyene phosphatidylcholine complex improve drug solubility. Acta Pharmacol Sin. 2011 Jan;32(1):108-15. doi: 10.1038/aps.2010.192. Epub 2010 Dec 20. PMID: 21170082; PMCID: PMC4003320.
31. Ashok, B. & Ayd, S. & Son, K. & Onyuksel, Hayat. (2004). Bile salt-phospholipid mixed micelles as solubilizers for water-insoluble drugs. Fabad Journal of Pharmaceutical Sciences. 28. 161-172.
32. Chih-Yang Cheng, Hyuntaek Oh, Ting-Yu Wang, Srinivasa R. Raghavan, and Shih-Huang Tung Langmuir 2014 30 (34), 10221-10230 DOI: 10.1021/la502380q
33. Wang NX, von Recum HA. Affinity-based drug delivery. Macromol Biosci. 2011 Mar 10;11(3):321-32. doi: 10.1002/mabi.201000206. Epub 2010 Nov 24. PMID: 21108454.
34. Belotserkovskiĭ MV, Gurevich K, Schumacher R, Dubikaitis A, Strashnov VI, Koniukhova SG.
35. [The use of the Lipostabil preparation in the combined efferent therapy of the clinical manifestations of an atherosclerotic process]. Ter Arkh. 1993;65(8):32-36
36. Lata J, Dastych M, Jr., Senkyrík M, Husová M, Starý K. [Protective effect of essential phospholipids on liver injury due to total parenteral nutrition]. Vnitr Lek 2001;47(9):599-603
37. Varkonyi G. [A contribution to therapeutic effects of oral and intravenous administration of essential choline phospholipids]. Z Gesamte Inn Med. 1962;17:830-834
38. Hasengschwandtner F, Gundermann KJ. Injection lipolysis with phosphatidylcholine and deoxycholate. Aesthetic Surgery Journal. 2013;33(7):1071-1072.
39. Williams KJ, Werth VP, Wolff JA. Intravenously administered lecithin liposomes: a synthetic antiatherogenic lipid particle. Perspect Biol Med. 1984;27(3):417-431.
40. Mel'chinskaia EN, Gromnatskiĭ NI, Kirichenko LL. Gipolipidemicheskie éffekty alisata i lipostabila u bol'nykh sakharnym diabetom [Hypolipidemic effects of alisat and lipostabil in patients with diabetes mellitus]. Ter Arkh. 2000;72(8):57-8. Russian. PMID: 11019431.

Distributed by:
European Biological Medicine Inc.

For inquiries:
Mobile: +63 969 235 6879 • +63 945 205 8514
Email: alfacholine@europeanwellnessretreat.com

Distributed by:
EUROPEAN BIOLOGICAL MEDICINE INC.

Researched and Innovated by:
STELLAR BIOMOLECULAR RESEARCH

MF PLUS LTD.
(2189275)

Ver5 08-2023

29th Floor, Spaces, World Plaza Building 5th Ave, Global City, Taguig, Metro Manila
www.europeanwellnessretreat.com

Disclaimer: The content in this website/brochure/leaflet should not be construed as medical advice. The information, including but not limited to text, images, and illustration, is for informational purposes only and not to substitute professional medical advice, diagnosis or treatment. Always seek advice from a physician or other qualified healthcare provider before taking our product.